Randomized Trialhigh evidence
Lonvoguran Ziclumeran - In Vivo CRISPR Gene Editing in Hereditary Angioedema.
The New England journal of medicine·June 13, 2026·PMID 42294842
Why it mattersThis trial provides high-level evidence for a novel, single-dose, disease-modifying approach to hereditary angioedema that directly targets the underlying genetic defect, potentially reducing long-term attack burden and the need for chronic prophylaxis.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled